AnandaCorProject reference: 685218
Funded under :
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
Concept and feasibility assessment for AnandaCor, a fast melting tablet, as a diagnostic device in ischemic heart conditions.
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Call for proposal:H2020-SMEINST-1-2015See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
Ouabain is a plant derived active pharmaceutical ingredient for specific heart diseases. In nanomolar doses the substance protects cardiomyocytes by stabilizing the Na+/K+ -ATPase. Ouabain enables ischemic preconditioning and has a balancing effect on the energy metabolism of cardiomyocytes by enhancing the turnover of lactate to ATP. Compared to similar substances this feature is unique to ouabain. It is also the fastest working of all cardiac glycosides, with a significantly different mode of action and a larger therapeutic range which means a smaller risk for unwanted side effects.
Ouabain targets mainly on the small vessels and the myocardial cell, rather than on the large vessels, and therefore can be useful to distinguish between relevant obstructive coronary atherosclerosis and the actual ischemia in the microvasculature or in the myocardial cell itself. These properties convey the great potential as a new diagnostic medical device for patients with angina pectoris due to ischemic heart conditions.
Therefore Ananda Pharma GmbH developed AnandaCor®, a fast melting tablet formulation of the active substance ouabain.
Since cardiovascular and ischemic heart conditions are highly prevalent in all industrialized countries, with over 2 million deaths per year and estimated external costs of nearly 110 billion € per annum in the European Union alone, there is an urgent need for effective diagnostic investigation.
EU contribution: EUR 50 000
KARL LIEBKNECHT STRASSE 94